OBJECTIVE: This study compared the effectiveness of risperidone and olanzapine in the treatment of delirium. METHODS: This was a 7-day, randomized, comparative clinical trial of risperidone and olanzapine in patients with delirium. The primary outcome measure was the Delirium Rating Scale-Revised-98 (DRS-R-98). RESULTS:We enrolled 32 subjects (median age, 70 years). Significant within-group improvements in the DRS-R-98 scores over time were observed at every time point in both treatment groups; however, differences in the change of the DRS-R-98 score from baseline were not significant between the treatment groups. On the first day after drug treatment, there was a trend toward greater improvement in the DRS-R-98 score in the olanzapine group compared with the risperidone group, but it did not reach statistical significance (p = 0.076). The response rates did not differ significantly between the two groups (risperidone group: 64.7%, olanzapine group: 73.3%). However, the response to risperidone was significantly poorer in patients >or=70 years of age compared with those aged <70 years. There was no significant difference in the safety profiles, including extrapyramidal symptoms (EPSs), between the two groups. CONCLUSION:Risperidone and olanzapine were equally effective in reducing delirium symptoms. The response to risperidone was poorer in the older age group.
RCT Entities:
OBJECTIVE: This study compared the effectiveness of risperidone and olanzapine in the treatment of delirium. METHODS: This was a 7-day, randomized, comparative clinical trial of risperidone and olanzapine in patients with delirium. The primary outcome measure was the Delirium Rating Scale-Revised-98 (DRS-R-98). RESULTS: We enrolled 32 subjects (median age, 70 years). Significant within-group improvements in the DRS-R-98 scores over time were observed at every time point in both treatment groups; however, differences in the change of the DRS-R-98 score from baseline were not significant between the treatment groups. On the first day after drug treatment, there was a trend toward greater improvement in the DRS-R-98 score in the olanzapine group compared with the risperidone group, but it did not reach statistical significance (p = 0.076). The response rates did not differ significantly between the two groups (risperidone group: 64.7%, olanzapine group: 73.3%). However, the response to risperidone was significantly poorer in patients >or=70 years of age compared with those aged <70 years. There was no significant difference in the safety profiles, including extrapyramidal symptoms (EPSs), between the two groups. CONCLUSION:Risperidone and olanzapine were equally effective in reducing delirium symptoms. The response to risperidone was poorer in the older age group.
Authors: Maurice J D L van der Vorst; Elisabeth C W Neefjes; Manon S A Boddaert; Bea A T T Verdegaal; Aart Beeker; Saskia C C Teunissen; Aartjan T F Beekman; Janneke A Wilschut; Johannes Berkhof; Wouter W A Zuurmond; Henk M W Verheul Journal: Oncologist Date: 2019-12-04
Authors: Shirley H Bush; Salmaan Kanji; José L Pereira; Daniel H J Davis; David C Currow; David Meagher; Kiran Rabheru; David Wright; Eduardo Bruera; Michael Hartwick; Pierre R Gagnon; Bruno Gagnon; William Breitbart; Laura Regnier; Peter G Lawlor Journal: J Pain Symptom Manage Date: 2014-01-28 Impact factor: 3.612
Authors: Giuseppe Bellelli; Alessandro Morandi; Marco Trabucchi; Guido Caironi; Daniele Coen; Carlo Fraticelli; Ciro Paolillo; Carolina Prevaldi; Angela Riccardi; Gianfranco Cervellin; Corrado Carabellese; Salvatore Putignano; Stefania Maggi; Antonio Cherubini; Paola Gnerre; Andrea Fontanella; Nicola Latronico; Concezione Tommasino; Antonio Corcione; Giovanni Ricevuti; Nicola Ferrara; Francesco De Filippi; Alberto Ferrari; Mario Guarino; Maria Pia Ruggieri; Pietro Amedeo Modesti; Carlo Locatelli; Patrizia Hrelia; Marco Otto Toscano; Emi Bondi; Antonio Tarasconi; Luca Ansaloni; Francesco Perticone Journal: Intern Emerg Med Date: 2017-07-24 Impact factor: 3.397
Authors: Anne M Finucane; Louise Jones; Baptiste Leurent; Elizabeth L Sampson; Patrick Stone; Adrian Tookman; Bridget Candy Journal: Cochrane Database Syst Rev Date: 2020-01-21
Authors: Karin J Neufeld; Jirong Yue; Thomas N Robinson; Sharon K Inouye; Dale M Needham Journal: J Am Geriatr Soc Date: 2016-03-23 Impact factor: 5.562